But results come from a curated dataset, with no in-trial comparator.
ApexOnco Front Page
Recent articles
Global data are in the same ballpark as Chinese results presented earlier this year.
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
Regeneron is facing two FDA decisions for its T-cell engagers.
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
